<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs reported to cause drug-induced thrombotic microangiopathy (DITMA)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs reported to cause drug-induced thrombotic microangiopathy (DITMA)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drugs reported to cause drug-induced thrombotic microangiopathy (DITMA)</div><div class="cntnt"><table cellspacing="0"><colgroup width="60%"></colgroup><colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Drug</td> <td class="subtitle1" colspan="2">Mechanism</td> </tr> <tr> <td class="subtitle2">Immune</td> <td class="subtitle2">Non-immune</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Antibiotics</td> </tr> <tr> <td class="indent1">Rifampin<sup>*</sup></td> <td class="centered"> </td> <td class="centered"> </td> </tr> <tr> <td class="indent1">Sulfisoxazole</td> <td class="centered">X</td> <td class="centered"> </td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole</td> <td class="centered">X</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Antipsychotics</td> </tr> <tr> <td class="indent1">Quetiapine</td> <td class="centered">X</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Antiseizure medications</td> </tr> <tr> <td class="indent1">Valproic acid</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Cancer therapies</td> </tr> <tr> <td class="indent1">Bevacizumab</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Bortezomib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Carfilzomib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Dasatinib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Docetaxel</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Gemcitabine</td> <td class="centered">X</td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Imatinib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Ixazomib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Mitomycin</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Oxaliplatin</td> <td class="centered">X</td> <td class="centered"> </td> </tr> <tr> <td class="indent1">Palbociclib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Pentostatin</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Ponatinib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Sunitinib</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Drugs of abuse</td> </tr> <tr> <td class="indent1">Cocaine</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Oxymorphone extended release (formulated with PEO, Opana ER)</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Oxycodone (OxyContin formulated with PEO)</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Gene therapy</td> </tr> <tr> <td class="indent1">Onasemnogene abeparvovec<sup>*</sup></td> <td class="centered"> </td> <td class="centered"> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Hemophilia A</td> </tr> <tr> <td class="indent1">Emicizumab</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Immunosuppressive therapies</td> </tr> <tr> <td class="indent1">Adalimumab</td> <td class="centered">X</td> <td class="centered"> </td> </tr> <tr> <td class="indent1">Cyclosporine</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Everolimus</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Infliximab</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Interferons (type 1, alpha and beta)</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Intravenous immune globulin (IVIG)</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Sirolimus</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="indent1">Tacrolimus</td> <td class="centered"> </td> <td class="centered">X</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Leg cramps, other minor symptoms, malaria (also as a beverage: tonic water, bitter lemon)</td> </tr> <tr> <td class="indent1">Quinine</td> <td class="centered">X</td> <td class="centered"> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The listed drugs are those that have been reported to have definite (≥1 report) or probable (≥2 reports) evidence for a causal association with DITMA. Published reports often described these syndromes as TTP or HUS. Some drugs that have been commonly reported to be associated with DITMA, such as clopidogrel, do not describe evidence supporting a definite or probable causal association. The presentation and prognosis differ between immune-mediated and toxicity-mediated DITMA. Refer to UpToDate topics on DITMA for details of evaluation and management.</div><div class="graphic_footnotes"><p>DITMA: drug-induced thrombotic microangiopathy; HUS: hemolytic uremic syndrome; PEO: polyethylene oxide; TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura.</p>
* For rifampin, supporting evidence is lacking; for rifampin and onasemnogene abeparvovec, the proposed mechanism (immune versus non-immune) is unknown.</div><div class="graphic_reference">Data from:
<ol>
<li>Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125:616.</li>
<li>Reese JA, Bougie DW, Curtis BR, et al. Drug-induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin. Am J Hematol 2015; 90:406.</li>
<li>Saleem R, Reese JA, George JN. Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018. Am J Hematol 2018; 93:E241.</li>
</ol></div><div id="graphicVersion">Graphic 101685 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
